1. Search Result
Search Result
Results for "

GLP-1r

" in MedChemExpress (MCE) Product Catalog:

70

Inhibitors & Agonists

19

Peptides

1

Inhibitory Antibodies

3

Recombinant Proteins

1

Antibodies

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-144034

    GCGR Metabolic Disease
    GLP-1R agonist 3 is a potent agonist of GLP-1R. GLP-1R agonist 3 is a thickened imidazole derivative compound. Glucagon-like peptide-1 (GLP-1) is an intestinal hypoglycemic hormone secreted by L-cells in the lower gastrointestinal tract. GLP-1R agonist 3 has the potential for the research of diabetes (extracted from patent WO2021197464A1, compound 1) [1].
    GLP-1R agonist 3
  • HY-144035

    GCGR Cancer
    GLP-1R agonist 4 is a potent agonist of GLP-1R. Glucagon-like peptide-1 (GLP-1) is an intestinal hypoglycemic hormone secreted by L-cells in the lower gastrointestinal tract. GLP-1R agonist 4 has the potential for the research of diabetes (extracted from patent WO2019239319A1, compound 96) [1].
    GLP-1R agonist 4
  • HY-101116
    GLP-1R Antagonist 1
    2 Publications Verification

    GCGR Metabolic Disease
    GLP-1R Antagonist 1 (compound 5d) is an orally active, CNS penetrant and non-competitive antagonist of glucagon-like peptide 1 receptor (GLP-1R), with an IC50 of 650 nM [1].
    GLP-1R Antagonist 1
  • HY-147625

    GLP Receptor Metabolic Disease
    GLP-1R agonist 12 (Compound 123) is an agonist of glucagon-like peptide-1 receptors (GLP-1R). GLP-1R agonist 12 can be used for diabetes research [1].
    GLP-1R agonist 12
  • HY-161915

    GLP Receptor Metabolic Disease
    GLP-1R agonist 23 (Example 376) is a GLP-1R agonist with an EC50 of 0.056 nM. GLP-1R agonist 23 can be used in diabetes research [1].
    GLP-1R agonist 23
  • HY-168585

    GLP Receptor Metabolic Disease
    GLP-1R agonist 26 (compound 1) is a glucagon-like peptide-1 receptor (GLP-1R) agonist with an EC50 of <10 nM [1].
    GLP-1R agonist 26
  • HY-144033

    GCGR Metabolic Disease
    GLP-1R agonist 1 is a potent agonist of GLP-1R. GLP-1R agonist 1 is a thickened imidazole derivative compound. Glucagon-like peptide-1 (GLP-1) is an intestinal hypoglycemic hormone secreted by L-cells in the lower gastrointestinal tract. GLP-1R agonist 1 has the potential for the research of diabetes (extracted from patent WO2021197464A1, compound 4) [1].
    GLP-1R agonist 1
  • HY-147622

    GCGR Metabolic Disease
    GLP-1R agonist 9 (Compound 96) is a GLP-1R agonist with EC50 values of 1.1 nM and 11 nM against CHO GLP-1R Clone H6 and CHO GLP-1R Clone C6, respectively [1].
    GLP-1R agonist 9
  • HY-144134

    GCGR Metabolic Disease
    GLP-1R agonist 6 is a potent GLP-1R agonist with an EC50 of 0.15 nM for human GLP-1R (WO2021249492A1, compound 005A or 005B) [1].
    GLP-1R agonist 6
  • HY-162979

    GLP Receptor Metabolic Disease
    GLP-1R agonist 25 (compound 13) is a GLP1-R agonist, with an EC50 of 0.167 nM. GLP-1R agonist 25 can be used in type II diabetes research [1].
    GLP-1R agonist 25
  • HY-141839

    GCGR Metabolic Disease
    GLP-1R modulator C16 is an allosteric modulator enhancing GLP-1 binding to GLP-1R via a transmembrane site (EC50 8.43 ± 3.82 μM).
    GLP-1R modulator C16
  • HY-141840

    GCGR Metabolic Disease
    GLP-1R modulator C5 is an allosteric modulator enhancing GLP-1 binding to GLP-1R via a transmembrane site (EC50 1.59 ± 0.53 μM).
    GLP-1R modulator C5
  • HY-160031

    GLP Receptor Cardiovascular Disease
    GLP-1R agonist 19 (M3190) is a potent and selective GLP-1R agonist. GLP-1R agonist 19 has excellent plasma stability, liver microsomal stability, and low hERG toxicity [1].
    GLP-1R agonist 19
  • HY-162306

    GLP Receptor Cancer
    GLP-1R agonist 18 (example 117) is an agonist for GLP-1R with an EC50 of 0.044 nM [1].
    GLP-1R agonist 18
  • HY-121835

    GCGR Metabolic Disease
    GLP-1R agonist 2 (compound 2) is an effective GLP-1R agonist that exerts its activating effect by forming hydrogen bonds with the Tyr42, Cys71, and Ser84 residues of GLP-1R. GLP-1R agonist 2 has the potential for research in metabolic diseases such as type 2 diabetes and obesity [1].
    GLP-1R agonist 2
  • HY-144136

    GCGR Metabolic Disease
    GLP-1R agonist 8 is a potent GLP-1R agonist with an EC50 of < 2 nM (WO2021219019A1, compound 129a) [1].
    GLP-1R agonist 8
  • HY-144133

    GCGR Metabolic Disease
    GLP-1R agonist 5 is a potent GLP-1R agonist with an EC50 of <10 nM (WO2021259309A1, compound 35) [1].
    GLP-1R agonist 5
  • HY-148212

    GCGR Cardiovascular Disease Metabolic Disease
    GLP-1R agonist 17 is a GLP-1 receptor agonist. GLP-1R agonist 17 shows excellent agonism on a GLP-1 receptor. GLP-1R agonist 17 can be used for the research of cardiovascular metabolic diseases [1].
    GLP-1R agonist 17
  • HY-144135

    GCGR Metabolic Disease
    GLP-1R agonist 7 is a potent GLP-1R agonist with an EC50 of 0.67 µM (WO2021244645A1, compound WXA001) [1].
    GLP-1R agonist 7
  • HY-141842

    GCGR Metabolic Disease
    GLP-1R modulator L7-028 is an allosteric modulator enhancing GLP-1 binding to GLP-1R via a transmembrane site (EC50 11.01 ± 2.73 μM).
    GLP-1R modulator L7-028
  • HY-147626

    GLP Receptor Metabolic Disease
    GLP-1R agonist 13 (Compound 24) is a GLP-1 receptor agonist [1].
    GLP-1R agonist 13
  • HY-147628

    GLP Receptor Metabolic Disease
    GLP-1R agonist 15 (Compound 101) is a GLP-1 receptor agonist [1].
    GLP-1R agonist 15
  • HY-147623

    GLP Receptor Metabolic Disease
    GLP-1R agonist 10 (Compound 109a) is a GLP-1 agonist with an EC50 of 0.051 nM [1].
    GLP-1R agonist 10
  • HY-147629

    GLP Receptor Metabolic Disease
    GLP-1R agonist 16 (Compound 115a) is a GLP-1 receptor agonist with an EC50 of 0.15 nM [1].
    GLP-1R agonist 16
  • HY-147627

    GLP Receptor Metabolic Disease
    GLP-1R agonist 14 (Compound 14) is a GLP-1 receptor agonist with an EC50 of 0-20 nM against h-GLP-1 [1].
    GLP-1R agonist 14
  • HY-162435

    GLP Receptor Metabolic Disease
    GLP-1R agonist 20 (Compound I-132) is an agonist for glucagon-like peptide-1 receptor (GLP-1 receptor), with EC50 of 0.0162 nM [1].
    GLP-1R agonist 20
  • HY-162436

    GLP Receptor Metabolic Disease
    GLP-1R agonist 21 (Compound I-134) is an agonist for glucagon-like peptide-1 receptor (GLP-1 receptor), with EC50 of 0.0104 nM [1].
    GLP-1R agonist 21
  • HY-162437

    GLP Receptor Metabolic Disease
    GLP-1R agonist 22 (Compound I-135) is an agonist for glucagon-like peptide-1 receptor (GLP-1 receptor), with EC50 of 0.0165 nM [1].
    GLP-1R agonist 22
  • HY-RS05490

    Small Interfering RNA (siRNA) Others

    GLP1R Human Pre-designed siRNA Set A contains three designed siRNAs for GLP1R gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    GLP1R Human Pre-designed siRNA Set A
    GLP1R Human Pre-designed siRNA Set A
  • HY-P10302A

    GLP Receptor Metabolic Disease
    GLP-1R/GIPR agonist-1 soduim is the sodium salt form of GLP-1R/GIPR agonist-1 (HY-P10302). GLP-1R/GIPR agonist-1 soduim is a dual agonist for glucagon-like peptide-1 receptor (GLP-1R, EC50 is 0.57 nM) and glucose-dependent insulin releasing peptide receptor (GIPR, EC50 is 0.75 nM). GLP-1R/GIPR agonist-1 soduim lowers blood sugar by mimicking the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 soduim can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH) [1].
    GLP-1R/GIPR agonist-1 (soduim)
  • HY-P10302

    GLP Receptor Insulin Receptor Metabolic Disease
    GLP-1R/GIPR AgonIST-1 is a double-receptor agonist for GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulin releasing peptide). GLP-1R/GIPR agonist-1 lowers blood sugar by mimicking the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH) [1].
    GLP-1R/GIPR agonist-1
  • HY-112679

    GCGR Others
    GLP-1 receptor agonist 2 is a glucagon-like peptide-1 receptor (GLP-1R) agonist.
    GLP-1 receptor agonist 2
  • HY-112185
    Orforglipron
    1 Publications Verification

    LY3502970; GLP-1 receptor agonist 1

    GCGR Metabolic Disease
    Orforglipron (LY3502970) (Compound 67) is an orally active agonist for Glucagon-like peptide-1 receptor (GLP-1R), which exhibits potency in ameliorates the type 2 diabete [1].
    Orforglipron
  • HY-112185A
    Orforglipron hemicalcium hydrate
    1 Publications Verification

    LY3502970 hemicalcium hydrate; GLP-1 receptor agonist 1 hemicalcium hydrate

    GCGR Metabolic Disease
    Orforglipron hemicalcium hydrate (LY3502970 hemicalcium hydrate; GLP-1 receptor agonist 1 hemicalcium hydrate) is the calcium salt hydrate form of Orforglipron (HY-112185). Orforglipron is an orally active agonist for Glucagon-like peptide-1 receptor (GLP-1R), which exhibits potency in ameliorating the type 2 diabete [1].
    Orforglipron hemicalcium hydrate
  • HY-129657

    GCGR Metabolic Disease
    GLP-1 receptor agonist 4 is a glucagon-like peptide-1 receptor (GLP-1R) agonist extracted from patent WO2009111700A2, compound 87, has an EC50 of 64.5 nM. GLP-1 receptor agonist 4 can be used in the research for treatment of diabetes [1].
    GLP-1 receptor agonist 4
  • HY-138996

    GCGR Metabolic Disease
    GLP-1 receptor agonist 8 is a potent agonist of GLP-1 R. GLP-1 receptor agonist 8 has the potential for the research of diabetes, obesity, and nonalcoholic fatty liver disease (NAFLD) (extracted from patent WO2019239319A1, compound 17) [1].
    GLP-1 receptor agonist 8
  • HY-153193

    GLP Receptor Metabolic Disease
    LSN3160440 is an allosteric modulator of GLP-1R, which acts as a protein–protein interaction (PPI) stabilizer or molecular glue to assist in the adhesion of inactive GLP-1 (9-36) NH2 on GLP-1R [1] .
    LSN3160440
  • HY-P10019

    NLY01

    GCGR Neurological Disease
    Pegsebrenatide (NLY01) is a long-acting GLP-1R agonist. Pegsebrenatide has an extended half-life and favorable blood-brain barrier penetration. Pegsebrenatide can block A1 astrocyte transformation, reducing dopaminergic cell death, and improving motor symptoms in mouse models of PD [1].
    Pegsebrenatide
  • HY-125824
    Danuglipron
    2 Publications Verification

    PF-06882961

    GCGR Metabolic Disease
    Danuglipron (PF-06882961) is an orally active glucagon-like peptide-1 receptor (GLP-1R) agonist. Danuglipron has the potential for type 2 diabetes research [1] .
    Danuglipron
  • HY-125824A

    PF-06882961 tromethamine

    GCGR Metabolic Disease
    Danuglipron (PF-06882961) tromethamine is an orally active glucagon-like peptide-1 receptor (GLP-1R) agonist. Danuglipron tromethamine has the potential for type 2 diabetes research [1] .
    Danuglipron tromethamine
  • HY-P3375

    IBI-362; LY-3305677; OXM-3

    GCGR GLP Receptor Metabolic Disease
    Mazdutide (IBI-362; LY-3305677) is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide binds human and mouse GCGR (Ki: 17.7 nM and 15.9 nM, respectively) and GLP-1R (Ki: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC50: 5.2 nM). Mazdutide is used in studies of obesity and type 2 diabetes (T2D) [1] .
    Mazdutide
  • HY-P3375A

    IBI-362 TFA; LY-3305677 TFA; OXM-3 TFA

    GCGR GLP Receptor Metabolic Disease
    Mazdutide (IBI-362; LY-3305677) TFA is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide TFA binds human and mouse GCGR (Ki: 17.7 nM and 15.9 nM, respectively) and GLP-1R (Ki: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC50: 5.2 nM). Mazdutide TFA is used in studies of obesity and type 2 diabetes (T2D) [1] .
    Mazdutide TFA
  • HY-142162

    GCGR Metabolic Disease
    LSN3318839 is an orally efficacious positive allosteric modulator of the glucagon-like peptide-1 receptor (GLP-1R).
    LSN3318839
  • HY-P3506
    Retatrutide
    1 Publications Verification

    LY3437943

    GCGR GLP Receptor Metabolic Disease
    Retatrutide (LY3437943) is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide binds human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity [1].
    Retatrutide
  • HY-P3506B

    LY3437943 acetate

    GCGR GLP Receptor Metabolic Disease
    Retatrutide (LY3437943) acetate is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide acetate inhibits human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide acetate can be used for the research of obesity [1].
    Retatrutide acetate
  • HY-P3506A
    Retatrutide TFA
    1 Publications Verification

    LY3437943 TFA

    GLP Receptor GCGR Metabolic Disease
    Retatrutide (LY3437943) TFA is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide TFA binds human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide TFA can be used for the research of obesity [1].
    Retatrutide TFA
  • HY-P10716

    GLP Receptor Metabolic Disease
    Exendin-P5 is a selective agonist that targets the GLP-1R. Exendin-P5 promotes rapid activation of G proteins by transient interactions with the transmembrane domain of GLP-1R, enhancing its potency in G protein-mediated signaling and accelerating cAMP production. This mechanism suggests the potential application of Exendin-P5 in the study of metabolic diseases [1].
    Exendin-P5
  • HY-P3539

    GCGR Neurological Disease Endocrinology
    Exendin-4 (3-39) is a peptide. Exendin-4 (3-39) is a truncated form of Exendin-4 (HY-13443) that lacks the first two amino acids. Exendin-4 is a potent Glucagon-like peptide-1 receptor (GLP-1r) agonist. Exendin-4 (3-39) and Exendin-4 can be used for the research of diabetic and hypothalamic-pituitary-adrenal (HPA) axis [1] .
    Exendin-4 (3-39)
  • HY-P4386

    GLP Receptor Metabolic Disease
    (Asp28)-Exenatide is a degradation product of exenatide (HY-13443). (Asp28)-Exenatide can be used as a GLP-1R agonist [1].
    (Asp28)-Exenatide
  • HY-153865

    PF-07081532

    GCGR Metabolic Disease
    Lotiglipron (PF-07081532) is an orally active GLP-1R agonist. Lotiglipron reduces glucose and body weight, and can be used for research of Type 2 diabetes mellitus (T2DM) [1].
    Lotiglipron

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: